News · 26 weeks23+100%
2026-04-192026-10-11
Mix990d
- Other3(33%)
- Insider3(33%)
- SEC Filings2(22%)
- Earnings1(11%)
Latest news
25 items- INSIDERSEC Form 4 filed by Penumbra Inc.4 - Penumbra Inc (0001321732) (Issuer)
- PRNew STORM-PE Data Demonstrate Correlation Between Clinical Assessments and Real-world Functional Recovery Captured Through Wearable Technology in Patients with Pulmonary EmbolismWearable-derived data provide new insights into how clinical outcomes for patients treated with CAVT and anticoagulation, and anticoagulation alone translate to patients' everyday recoveryALAMEDA, Calif., Oct. 6, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN) announced results from a subset analysis of the landmark STORM-PE randomized controlled trial (RCT), the first trial to demonstrate a significant correlation between real-world, daily step-based activity as captured on a consumer wearable device and patient performance in the clinical 6-minute walk test. The findings were presented at this week's Vascular InterVentional Advances (VIVA) meeting.STORM-PE RCT assessed patients with acute i
- INSIDERPresident Narayan Shruthi covered exercise/tax liability with 1,230 shares, decreasing direct ownership by 4% to 32,650 units (SEC Form 4) to satisfy withholding obligation4 - Penumbra Inc (0001321732) (Issuer)
- INSIDERPresident Narayan Shruthi was granted 3,060 shares, increasing direct ownership by 10% to 33,880 units (SEC Form 4)4 - Penumbra Inc (0001321732) (Issuer)
- SECSEC Form SCHEDULE 13G filed by Penumbra Inc.SCHEDULE 13G - Penumbra Inc (0001321732) (Subject)
- SECSEC Form 10-Q filed by Penumbra Inc.10-Q - Penumbra Inc (0001321732) (Filer)
- SECPenumbra Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Penumbra Inc (0001321732) (Filer)
- PRPenumbra, Inc. Reports Second Quarter 2026 Financial ResultsALAMEDA, Calif., July 30, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN), the world's leading thrombectomy company, today reported financial results for the second quarter ended June 30, 2026. Revenue of $390.0 million in the second quarter of 2026, an increase of 14.9% compared to the second quarter of 2025.Global thrombectomy revenue of $259.0 million in the second quarter of 2026, an increase of 12.5% compared to the second quarter of 2025.Global embolization and access revenue of $131.1 million in the second quarter of 2026, an increase of 20.0% compared to the second quarter of 2025.Gross profit margin of 67.9% in the seco
- PRTHUNDER Study Demonstrates Penumbra's THUNDERBOLT is Safe and Effective for Stroke CareFirst and only CAVT device for stroke demonstrated high revascularization rates, short procedure times and low complication ratesALAMEDA, Calif., July 22, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN), the world's leading thrombectomy company, announced the results of THUNDER, an Investigational Device Exemption (IDE) study, to evaluate the safety and effectiveness of THUNDERBOLT™, the company's novel computer assisted vacuum thrombectomy (CAVT™) system, in stroke patients with emergent large vessel occlusion (ELVO). The data were presented this week during a late-breaking session at the Society of NeuroInterventional Surgery (SNIS) 23rd Annual Meeting.
- PRFirst Patient Enrolled in Penumbra's FORWARD Study Evaluating Mechanical Thrombectomy and Computer Assisted Vacuum Thrombectomy for Distal Acute Ischemic StrokeALAMEDA, Calif., July 7, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN), the world's leading thrombectomy company, announced the initiation of its FORWARD study, an international, real world prospective, multi-center study. The study will collect safety and efficacy data on mechanical thrombectomy, including computer assisted vacuum thrombectomy (CAVT™) and modulated aspiration, in the management of acute ischemic stroke with distal occlusions. The first patient was treated by Keith Woodward, M.D., neurointerventional radiologist at Vista Radiology in Knoxville, Tenn. "Distal occlusions are among the more difficult strokes to
- SECPenumbra Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Penumbra Inc (0001321732) (Filer)
- PRPenumbra Expands CAVT for Stroke to Europe with CE Mark for THUNDERBOLTThe THUNDERBOLT TM Computer Assisted Vacuum Thrombectomy (CAVTTM) technology introduces modulated aspiration for acute ischemic stroke for the first time, enabling more rapid, complete clot removalALAMEDA, Calif., June 15, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN), the world's leading thrombectomy company, announced it has secured CE Mark in Europe for THUNDERBOLT™, further laying the groundwork for launching computer assisted vacuum thrombectomy (CAVT™) technology to address acute ischemic stroke globally. The company received U.S. Food and Drug Administration clearance last week. "Stroke is the second leading cause of de
- PRPenumbra's THUNDERBOLT Receives FDA Clearance - Bringing Computer Assisted Vacuum Thrombectomy Technology to StrokeTHUNDERBOLT is the first CAVT platform to deliver modulated aspiration for acute ischemic stroke — enabling faster, more complete clot removalALAMEDA, Calif., June 11, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN), the world's leading thrombectomy company, announced it has received U.S. Food and Drug Administration (FDA) clearance for THUNDERBOLT™, expanding its computer assisted vacuum thrombectomy (CAVT™) technology to address acute ischemic stroke. "Stroke is the second leading cause of death worldwide and with stroke, timing is critical. If the blood clot isn't removed and the artery reopened quickly, patients can face sev
- SECSEC Form SD filed by Penumbra Inc.SD - Penumbra Inc (0001321732) (Filer)
- INSIDERCEO Elsesser Adam gifted 77,000 shares (SEC Form 4)4 - Penumbra Inc (0001321732) (Issuer)
- SECSEC Form 425 filed by Penumbra Inc.425 - Penumbra Inc (0001321732) (Subject)
- SECPenumbra Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Penumbra Inc (0001321732) (Filer)
- SECSEC Form 10-Q filed by Penumbra Inc.10-Q - Penumbra Inc (0001321732) (Filer)
- SECPenumbra Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Penumbra Inc (0001321732) (Filer)
- SECSEC Form DEFA14A filed by Penumbra Inc.DEFA14A - Penumbra Inc (0001321732) (Filer)
- SECSEC Form DEF 14A filed by Penumbra Inc.DEF 14A - Penumbra Inc (0001321732) (Filer)
- SECSEC Form 425 filed by Penumbra Inc.425 - Penumbra Inc (0001321732) (Subject)
- SECSEC Form 425 filed by Penumbra Inc.425 - Penumbra Inc (0001321732) (Subject)
- SECSEC Form 425 filed by Penumbra Inc.425 - Penumbra Inc (0001321732) (Subject)
- PRNew STORM-PE Data Show Computer Assisted Vacuum Thrombectomy with Anticoagulation Resulted in Significantly Better Functional Outcomes at 90 Days Compared to Anticoagulation Alone for Pulmonary Embolism PatientsALAMEDA, Calif., April 13, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN) announced 90-day results of the landmark STORM-PE randomized controlled trial (RCT), which found that patients with acute intermediate-high risk pulmonary embolism (PE) who were treated with computer assisted vacuum thrombectomy (CAVT™) plus anticoagulation achieved greater functional improvement, including walking significantly further and a higher proportion of patients achieving NYHA Class I (no physical limitations), compared to anticoagulation alone. The first-of-its kind data were presented at this week's Society of Interventional Radiology (SIR) Annual Scientific Meeting.
PEN FAQ
7 questionsWhat does Penumbra Inc. do?
Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400...Where does PEN stock trade?
Penumbra Inc. (PEN) is listed on NYSE.What sector and industry is PEN in?
Penumbra Inc. operates in the Health Care sector, Medical/Dental Instruments industry.When did Penumbra Inc. go public?
Penumbra Inc. (PEN) completed its IPO in 2015.What are analysts saying about PEN?
Penumbra Inc. has had 8 recent analyst actions on file. The most recent action was from Analyst: Overweight on 2025-12-18. Recent price targets cluster around $1500.00.What companies are similar to PEN?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), BDX (Becton Dickinson and Company), MDLN (Medline Inc.). Compare PEN side-by-side with any of them on Quantisnow.How can I track PEN on Quantisnow?
Quantisnow aggregates Penumbra Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PEN to receive live email and push alerts on every new disclosure.